NCT02558595 is a Phase 2 clinical trial of Niacinamide in Polycystic Kidney Disease, sponsored by University of Kansas Medical Center.

Who is sponsoring NCT02558595?

NCT02558595 is sponsored by University of Kansas Medical Center.

What drugs are being tested in NCT02558595?

Interventions in NCT02558595: Niacinamide, Placebo.

What condition does NCT02558595 study?

NCT02558595 studies Polycystic Kidney Disease.

Is NCT02558595 still recruiting?

NCT02558595 is currently completed. Last updated 11 February 2019.

Last reviewed 2019-02-11 · How we verify

NCT02558595

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)

Completed Phase 2 Last updated 11 February 2019

What this trial tests

Phase 2 trial testing Niacinamide in Polycystic Kidney Disease in 36 participants. Completed in 18 December 2017.

Timeline

22 September 2015

Primary endpoint
18 December 2017

18 December 2017

Quick facts

Lead sponsor	University of Kansas Medical Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	basic science
Enrollment	36
Start date	22 September 2015
Primary completion	18 December 2017
Estimated completion	18 December 2017
Sites	1 location across United States

Drugs / interventions tested

Niacinamide — full drug profile →
Placebo

Conditions studied

Polycystic Kidney Disease — all drugs for Polycystic Kidney Disease →

Sponsor

University of Kansas Medical Center

Who can join

Adults 18 to 60, any sex, with Polycystic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to observe the effects of niacinamide on markers of kidney injury, inflammation, kidney cyst growth and kidney function.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

NAD<sup>+</sup> metabolism: pathophysiologic mechanisms and therapeutic potential.
Xie N, Zhang L, Gao W, Huang C, et al · · 2020 · cited 744× · PMID 33028824 · DOI 10.1038/s41392-020-00311-7
Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.
Nowak KL, Hopp K. · · 2020 · cited 89× · PMID 32086281 · DOI 10.2215/cjn.13291019
Niacin for primary and secondary prevention of cardiovascular events.
Schandelmaier S, Briel M, Saccilotto R, Olu KK, et al · · 2017 · cited 59× · PMID 28616955 · DOI 10.1002/14651858.cd009744.pub2
Management of autosomal-dominant polycystic kidney disease-state-of-the-art.
Müller RU, Benzing T. · · 2018 · cited 29× · PMID 30581561 · DOI 10.1093/ckj/sfy103
Molecular Mechanisms of Epigenetic Regulation, Inflammation, and Cell Death in ADPKD.
Agborbesong E, Li LX, Li L, Li X. · · 2022 · cited 25× · PMID 35847973 · DOI 10.3389/fmolb.2022.922428
Biological Efficacy and Safety of Niacinamide in Patients With ADPKD.
El Ters M, Zhou X, Lepping RJ, Lu P, et al · · 2020 · cited 23× · PMID 32775826 · DOI 10.1016/j.ekir.2020.06.002
Nicotinamide and acute kidney injury.
Fontecha-Barriuso M, Lopez-Diaz AM, Carriazo S, Ortiz A, et al · · 2021 · cited 22× · PMID 34950458 · DOI 10.1093/ckj/sfab173
Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.
Benz EG, Hartung EA. · · 2021 · cited 20× · PMID 33474686 · DOI 10.1007/s00467-020-04869-w

Verify or expand the search:

Other trials of Niacinamide

Trials testing the same drug.

NCT04750616 — NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial · Phase 2 · recruiting
NCT03808961 — Low Dose Niacin (Vitamin B3) for Parkinson's Disease · NA · terminated
NCT03392623 — DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide. · EARLY_PHASE1 · completed

Other recruiting trials for Polycystic Kidney Disease

Currently open trials in the same condition.

NCT06728228 — Amnioinfusion for Fetal Renal Failure · NA · recruiting
NCT06325644 — Well-Formulated Ketogenic Diet Polycystic Kidney Disease · NA · recruiting

Other University of Kansas Medical Center trials

Trials by the same sponsor.

NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02558595 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
Last refreshed: 11 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02558595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing